(12-192) Evaluation of Amyloid-Related Imaging Abnormality (ARIA) Rates in Patients Rechallenged with Donanemab or Lecanemab after Initial ARIA Event

Wednesday, December 10, 2025

2:00 PM - 3:00 PM

Location: Bayside A, Level 1

Residency Program: University Hospitals Specialty Pharmacy Services
Residency Program Type: PGY1 (Pharmacy)
Residency Program Location: Ohio

Co-Author(s): Kyle Duale, Mohamed Elkasaby, Rajeet Shrestha

Primary Author(s)

Madelyn Braman, PharmD

Pharmacy Resident
University Hospitals Specialty Pharmacy